TY - JOUR
T1 - De Novo GMNN Mutations Cause Autosomal-Dominant Primordial Dwarfism Associated with Meier-Gorlin Syndrome
AU - Burrage, Lindsay C.
AU - Charng, Wu Lin
AU - Eldomery, Mohammad K.
AU - Willer, Jason R.
AU - Davis, Erica Ellen
AU - Lugtenberg, Dorien
AU - Zhu, Wenmiao
AU - Leduc, Magalie S.
AU - Akdemir, Zeynep C.
AU - Azamian, Mahshid
AU - Zapata, Gladys
AU - Hernandez, Patricia P.
AU - Schoots, Jeroen
AU - De Munnik, Sonja A.
AU - Roepman, Ronald
AU - Pearring, Jillian N.
AU - Jhangiani, Shalini
AU - Katsanis, Elias Nicholas
AU - Vissers, Lisenka E.L.M.
AU - Brunner, Han G.
AU - Beaudet, Arthur L.
AU - Rosenfeld, Jill A.
AU - Muzny, Donna M.
AU - Gibbs, Richard A.
AU - Eng, Christine M.
AU - Xia, Fan
AU - Lalani, Seema R.
AU - Lupski, James R.
AU - Bongers, Ernie M.H.F.
AU - Yang, Yaping
N1 - Funding Information:
We thank the patients and their families for participating in this study. We also thank S.D. van der Velde-Visser for technical support. This work was funded in part by the US National Human Genome Research Institute (NHGRI)/National Heart Lung and Blood Institute (NHLBI) grant number U54HG006542 to the Baylor-Hopkins Center for Mendelian Genomics (BH-CMG). L.C.B. was supported by the Genzyme/ACMG Foundation for Genetic and Genomic Medicine Medical Genetics Training Award in Clinical Biochemical Genetics, the National Urea Cycle Disorders Foundation Fellowship, a fellowship from the Urea Cycle Disorders Consortium (UCDC; U54HD061221), which is a part of the National Institutes of Health (NIH) Rare Disease Clinical Research Network (RDCRN), supported through collaboration between the Office of Rare Diseases Research (ORDR), the National Center for Advancing Translational Science (NCATS and the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), and the National Institutes of Health (T32 GM07526). W.-L.C. is supported by CPRIT training Program RP140102. N.K. is supported by P50 DK096415 and is a distinguished Jean and George Brumley Professor. J.R.L. holds stock ownership in 23andMe and Lasergen, is a paid consultant for Regeneron Pharmaceuticals, and is a co-inventor of multiple United States and European patents related to molecular diagnostics. The Department of Molecular and Human Genetics at Baylor College of Medicine derives revenue from molecular genetic testing offered in the Baylor Miraca Genetics Laboratories.
Publisher Copyright:
© 2015 The American Society of Human Genetics.
PY - 2015/12/3
Y1 - 2015/12/3
N2 - Meier-Gorlin syndrome (MGS) is a genetically heterogeneous primordial dwarfism syndrome known to be caused by biallelic loss-of-function mutations in one of five genes encoding pre-replication complex proteins: ORC1, ORC4, ORC6, CDT1, and CDC6. Mutations in these genes cause disruption of the origin of DNA replication initiation. To date, only an autosomal-recessive inheritance pattern has been described in individuals with this disorder, with a molecular etiology established in about three-fourths of cases. Here, we report three subjects with MGS and de novo heterozygous mutations in the 5′ end of GMNN, encoding the DNA replication inhibitor geminin. We identified two truncating mutations in exon 2 (the 1st coding exon), c.16A>T (p.Lys6∗) and c.35-38delTCAA (p.Ile12Lysfs∗4), and one missense mutation, c.50A>G (p.Lys17Arg), affecting the second-to-last nucleotide of exon 2 and possibly RNA splicing. Geminin is present during the S, G2, and M phases of the cell cycle and is degraded during the metaphase-anaphase transition by the anaphase-promoting complex (APC), which recognizes the destruction box sequence near the 5′ end of the geminin protein. All three GMNN mutations identified alter sites 5′ to residue Met28 of the protein, which is located within the destruction box. We present data supporting a gain-of-function mechanism, in which the GMNN mutations result in proteins lacking the destruction box and hence increased protein stability and prolonged inhibition of replication leading to autosomal-dominant MGS.
AB - Meier-Gorlin syndrome (MGS) is a genetically heterogeneous primordial dwarfism syndrome known to be caused by biallelic loss-of-function mutations in one of five genes encoding pre-replication complex proteins: ORC1, ORC4, ORC6, CDT1, and CDC6. Mutations in these genes cause disruption of the origin of DNA replication initiation. To date, only an autosomal-recessive inheritance pattern has been described in individuals with this disorder, with a molecular etiology established in about three-fourths of cases. Here, we report three subjects with MGS and de novo heterozygous mutations in the 5′ end of GMNN, encoding the DNA replication inhibitor geminin. We identified two truncating mutations in exon 2 (the 1st coding exon), c.16A>T (p.Lys6∗) and c.35-38delTCAA (p.Ile12Lysfs∗4), and one missense mutation, c.50A>G (p.Lys17Arg), affecting the second-to-last nucleotide of exon 2 and possibly RNA splicing. Geminin is present during the S, G2, and M phases of the cell cycle and is degraded during the metaphase-anaphase transition by the anaphase-promoting complex (APC), which recognizes the destruction box sequence near the 5′ end of the geminin protein. All three GMNN mutations identified alter sites 5′ to residue Met28 of the protein, which is located within the destruction box. We present data supporting a gain-of-function mechanism, in which the GMNN mutations result in proteins lacking the destruction box and hence increased protein stability and prolonged inhibition of replication leading to autosomal-dominant MGS.
UR - http://www.scopus.com/inward/record.url?scp=84951788229&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84951788229&partnerID=8YFLogxK
U2 - 10.1016/j.ajhg.2015.11.006
DO - 10.1016/j.ajhg.2015.11.006
M3 - Article
C2 - 26637980
AN - SCOPUS:84951788229
SN - 0002-9297
VL - 97
SP - 904
EP - 913
JO - American Journal of Human Genetics
JF - American Journal of Human Genetics
IS - 6
ER -